PCI Pharma Services, a pharma/biopharma outsourcing provider, has unveiled an expansion of its plant in Rockford, Illinois, featuring additional primary and secondary packaging as well as labelling of clinical supplies.
The 30,000-square-foot expansion also includes a temperature-controlled suite.
Construction on the project began in November last year and was recently completed. The cost of the project wasn’t disclosed. The expansion also includes a new customer reception area and additional office space.
“This investment is one of many PCI is making across our global clinical supply chain in strategic location in the U.S., U.K., Europe and Australia to ensure we can meet our clients’ global needs by packaging and delivering life-saving therapeutic products to patients worldwide,” Brad Payne, PCI’s chief operating officer, said in a statement.
Earlier this year, PCI announced it would boost its capacity for clinical services with the addition of a 75,000-square-foot facility near Dublin that can serve as both a primary and secondary packaging, storage, logistics and distribution center.
At the time of that announcement, Salim Haffar, PCI’s chief executive, said the company’s strategy was to continue to expand its global network in support of growing customer demand as well as provide a solution for Brexit through ongoing investment in capacity, capability expansion and talent.
PCI, like CDMOs such as Almac and Wasdell Group, has been expanding its footprint—particularly in Ireland—to prepare for disruption in the pharmaceutical market that is likely to occur with Brexit.